Therapeutic proteins provide unique treatments for numerous human diseases and disorders including cancer, multiple sclerosis, hemophilia, rheumatoid arthritis, Crohn's disease and diabetes. Unfortunately, in significant fractions of patients receiving therapeutic protein products (up to 50% or higher), efficacy is lost due to immune response to the product. Immunogenicity may be stimulated by the presence of protein aggregates. In this project, we will use a hierarchical approach that uses advanced computer simulations combined with state-of-the art experiments to provide detailed, molecular-level information on the mechanisms by which protein aggregation occurs. Experiments will utilize synthetic proteins with designed chemical characteristics, model therapeutic proteins in murine models and commercial therapeutic proteins. Protein aggregates and pathways for their formation will be analyzed using a wide array of experimental techniques including single-molecule total internal reflectance fluorescence-Forster resonant energy transfer, small angle neutron scattering, small angle x-ray scattering micro-flow imaging, surface micro-rheology, chromatography, circular dichroism spectroscopy and infrared spectroscopy. A major focus of this renewal proposal will be the extension of our current work on protein aggregation in homogeneous solutions to protein aggregation that occurs due to interactions with interfaces such as those found in delivery devices (e.g., syringes, IV bags, IV lines, and delivery pumps).
Aggregates formed within formulations of therapeutic proteins pose a risk for patient safety by increasing risk for adverse immune responses. By understanding the fundamental mechanisms that lead to therapeutic protein aggregation and associated immune responses, interdiction strategies can be developed that enhance the safety and efficacy of this valuable class of therapeutic molecules.
|Barnett, Gregory V; Drenski, Michael; Razinkov, Vladimir et al. (2016) Identifying protein aggregation mechanisms and quantifying aggregation rates from combined monomer depletion and continuousÂ scattering. Anal Biochem 511:80-91|
|Jiskoot, Wim; Kijanka, Grzegorz; Randolph, Theodore W et al. (2016) Mouse Models for Assessing Protein Immunogenicity: Lessons and Challenges. J Pharm Sci 105:1567-75|
|Snell, Jared R; Zhou, Chen; Carpenter, John F et al. (2016) Particle Formation and Aggregation of a Therapeutic Protein in Nanobubble Suspensions. J Pharm Sci 105:3057-63|
|Shao, Qing; Hall, Carol K (2016) Allosteric effects of gold nanoparticles on human serum albumin. Nanoscale :|
|Wang, Yiming; Shao, Qing; Hall, Carol K (2016) N-terminal Prion Protein Peptides (PrP(120-144)) Form Parallel In-register Î²-Sheets via Multiple Nucleation-dependent Pathways. J Biol Chem 291:22093-22105|
|Chisholm, Carly Fleagle; Baker, Abby E; Soucie, Kaitlin R et al. (2016) Silicone Oil Microdroplets Can Induce Antibody Responses Against Recombinant Murine Growth Hormone in Mice. J Pharm Sci 105:1623-32|
|Xiao, Xingqing; Hung, Michelle E; Leonard, Joshua N et al. (2016) Adding energy minimization strategy to peptide-design algorithm enables better search for RNA-binding peptides: Redesigned Î» N peptide binds boxB RNA. J Comput Chem 37:2423-35|
|Zhao, Binwu; Li, Nan K; Yingling, Yaroslava G et al. (2016) LCST Behavior is Manifested in a Single Molecule: Elastin-Like polypeptide (VPGVG)n. Biomacromolecules 17:111-8|
|Pardeshi, Neha N; Qi, Wei; Dahl, Kevin et al. (2016) Microparticles and Nanoparticles Delivered in Intravenous Saline and in an Intravenous Solution of a Therapeutic Antibody Product. J Pharm Sci :|
|Sorret, Lea L; DeWinter, Madison A; Schwartz, Daniel K et al. (2016) Challenges in Predicting Protein-Protein Interactions from Measurements of Molecular Diffusivity. Biophys J 111:1831-1842|
Showing the most recent 10 out of 82 publications